267 related articles for article (PubMed ID: 30651332)
1. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma.
Caragher SP; Shireman JM; Huang M; Miska J; Atashi F; Baisiwala S; Hong Park C; Saathoff MR; Warnke L; Xiao T; Lesniak MS; James CD; Meltzer H; Tryba AK; Ahmed AU
J Neurosci; 2019 Mar; 39(11):1982-1993. PubMed ID: 30651332
[TBL] [Abstract][Full Text] [Related]
2. Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells.
Li Y; Wang W; Wang F; Wu Q; Li W; Zhong X; Tian K; Zeng T; Gao L; Liu Y; Li S; Jiang X; Du G; Zhou Y
J Mol Cell Biol; 2017 Aug; 9(4):302-314. PubMed ID: 28486630
[TBL] [Abstract][Full Text] [Related]
3. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
[TBL] [Abstract][Full Text] [Related]
4. Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5.
Jeon HM; Oh YT; Shin YJ; Chang N; Kim D; Woo D; Yeup Y; Joo KM; Jo H; Yang H; Lee JK; Kang W; Sa J; Lee WJ; Hale J; Lathia JD; Purow B; Park MJ; Park JB; Nam DH; Lee J
Neoplasia; 2023 May; 39():100894. PubMed ID: 36972629
[TBL] [Abstract][Full Text] [Related]
5. The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells.
Weissenrieder JS; Reed JL; Green MV; Moldovan GL; Koubek EJ; Neighbors JD; Hohl RJ
Pharmacology; 2020; 105(1-2):19-27. PubMed ID: 31645049
[TBL] [Abstract][Full Text] [Related]
6. Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop.
Wang Y; Wang X; Wang K; Qi J; Zhang Y; Wang X; Zhang L; Zhou Y; Gu L; Yu R; Zhou X
J Exp Clin Cancer Res; 2023 Jul; 42(1):161. PubMed ID: 37415171
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma.
Li J; Zhu S; Kozono D; Ng K; Futalan D; Shen Y; Akers JC; Steed T; Kushwaha D; Schlabach M; Carter BS; Kwon CH; Furnari F; Cavenee W; Elledge S; Chen CC
Oncotarget; 2014 Feb; 5(4):882-93. PubMed ID: 24658464
[TBL] [Abstract][Full Text] [Related]
8. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo.
Lamour V; Henry A; Kroonen J; Nokin MJ; von Marschall Z; Fisher LW; Chau TL; Chariot A; Sanson M; Delattre JY; Turtoi A; Peulen O; Rogister B; Castronovo V; Bellahcène A
Int J Cancer; 2015 Sep; 137(5):1047-57. PubMed ID: 25620078
[TBL] [Abstract][Full Text] [Related]
9. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma.
He L; Bhat K; Ioannidis A; Zhang L; Nguyen NT; Allen JE; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
Radiother Oncol; 2021 Aug; 161():140-147. PubMed ID: 34097975
[TBL] [Abstract][Full Text] [Related]
10. Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells.
D'Alessio A; Proietti G; Lama G; Biamonte F; Lauriola L; Moscato U; Vescovi A; Mangiola A; Angelucci C; Sica G
Oncotarget; 2016 Nov; 7(48):78541-78556. PubMed ID: 27705944
[TBL] [Abstract][Full Text] [Related]
11. Eva1 Maintains the Stem-like Character of Glioblastoma-Initiating Cells by Activating the Noncanonical NF-κB Signaling Pathway.
Ohtsu N; Nakatani Y; Yamashita D; Ohue S; Ohnishi T; Kondo T
Cancer Res; 2016 Jan; 76(1):171-81. PubMed ID: 26677976
[TBL] [Abstract][Full Text] [Related]
12. p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment.
Agrawal R; Garg A; Benny Malgulwar P; Sharma V; Sarkar C; Kulshreshtha R
Int J Cancer; 2018 May; 142(9):1817-1828. PubMed ID: 29226333
[TBL] [Abstract][Full Text] [Related]
13. Monoamines in glioblastoma: complex biology with therapeutic potential.
Caragher SP; Hall RR; Ahsan R; Ahmed AU
Neuro Oncol; 2018 Jul; 20(8):1014-1025. PubMed ID: 29126252
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis.
Joseph JV; Conroy S; Pavlov K; Sontakke P; Tomar T; Eggens-Meijer E; Balasubramaniyan V; Wagemakers M; den Dunnen WF; Kruyt FA
Cancer Lett; 2015 Apr; 359(1):107-16. PubMed ID: 25592037
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.
Nigim F; Cavanaugh J; Patel AP; Curry WT; Esaki S; Kasper EM; Chi AS; Louis DN; Martuza RL; Rabkin SD; Wakimoto H
J Neuropathol Exp Neurol; 2015 Jul; 74(7):710-22. PubMed ID: 26083570
[TBL] [Abstract][Full Text] [Related]
16. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal.
Lulli V; Buccarelli M; Martini M; Signore M; Biffoni M; Giannetti S; Morgante L; Marziali G; Ilari R; Pagliuca A; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Oncotarget; 2015 Nov; 6(35):37241-56. PubMed ID: 26437223
[TBL] [Abstract][Full Text] [Related]
17. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4.
Yi L; Zhou X; Li T; Liu P; Hai L; Tong L; Ma H; Tao Z; Xie Y; Zhang C; Yu S; Yang X
J Exp Clin Cancer Res; 2019 Aug; 38(1):339. PubMed ID: 31382985
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
20. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.
Xu H; Rahimpour S; Nesvick CL; Zhang X; Ma J; Zhang M; Zhang G; Wang L; Yang C; Hong CS; Germanwala AV; Elder JB; Ray-Chaudhury A; Yao Y; Gilbert MR; Lonser RR; Heiss JD; Brady RO; Mao Y; Qin J; Zhuang Z
Oncotarget; 2015 May; 6(14):11882-93. PubMed ID: 25957416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
